Please login to the form below

Not currently logged in
Email:
Password:

ABPI appoints head of commercial affairs

Carol Blount has joined the Association of the British Pharmaceutical Industry as head of commercial affairs

Carol Blount has joined the Association of the British Pharmaceutical Industry (ABPI) as head of commercial affairs.

She joins the ABPI with more than 15 years' senior level leadership experience within UK pharma including leadership of strategic innovation and change, business development and brand marketing. She has worked previously for Bayer and AstraZeneca.

 

Carol Blount
Carol Blount

 

In her new role, she is responsible for managing all commercial affairs and initiatives within the ABPI, including NHS Joint Working and quality innovation, prevention and productivity (QIPP) initiatives, delivery of commercial aspects of Pharmaceutical Price Regulation Scheme (PPRS), supply chain and distribution initiatives.

Carol commented: "With a new government and an uncertain financial situation throughout the world, these are challenging times for our industry. I am very much looking forward to working in my new role to help tackle some of the vitally important issues facing the industry."

Alison Clough, ABPI Commercial and Communications director said: "I am delighted that Carol is joining our strengthened commercial team. Her extensive experience will bring added value to our activities working with the NHS on QIPP, as well as supply shortages and other commercial issues."

15th June 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Main image2
Customers, content and change
By Dominic Tyer...
Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...